Calcineurin Inhibitors and the IL12A Locus Influence Risk of Recurrent Primary Biliary Cirrhosis After Liver Transplantation
Year: 2013
Type: article
Abstract: To the Editor: Genomewide association studies and Illumina immunoarray (iCHIP) association studies of primary biliary cirrhosis (PBC) have identified 29 genetic loci associated with disease. We hypothesized that risk loci for PBC in the native liver might influence the risk of PBC recurring after liver transplantation (LT). To address this hypothesis, we analyzed 248 PBC LT recipients for whom genotype data were available from the Wellcome Trust Case-Control Consortium (WTCCC3) iCHIP association study of PBC (1Liu JZ Almarri MA Gaffney DJ et al.Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis.Nat Genet. 2012; 44: 1137-1141Crossref PubMed Scopus (210) Google Scholar). Recurrent PBC (rPBC) was defined as a liver allograft biopsy (protocol or event) showing at least two of the following abnormalities in the portal tracts: lymphocytic cell infiltrate, lymphoid aggregates, granulomas or bile duct lesions. One hundred and five (42.3%) LT recipients developed rPBC (median time to recurrence: 61.8 months; 25–75%, IQR: 16.7–103.8). On univariate analysis the following variables influenced the risk of rPBC: calcineurin-inhibitor (CNI) selection at induction (Cyclosporin vs. Tacrolimus: hazard ratio [HR] = 0.47, p = 0.001); CNI selection at 1-year (HR = 0.40, p = 9.8×10−5), the SNPs rs62270414 (HR = 1.4, p = 0.04) and rs668998 (HR = 0.68, p = 0.015) at 3q25 (IL12A locus), and the SNP rs11117433 (HR = 0.6, p = 0.045) at 16q24 (IRF8 locus). In multivariate analysis using the Cox model, only CNI selection at 1-year and rs62270414 were significant. The final model consisted of CNI selection at 1-year (HR = 2.77, 95% CI 1.6–5.0, p = 2.7×10−5) and rs62270414 (risk allele G, HR = 1.65, 95% CI 1.1–2.4, p = 0.008) (Figure 1). We report for the first time the association of rPBC with the IL12A locus. This observation is highly plausible given the strong association between variants at the IL12A locus and susceptibility to PBC in native liver (2Hirschfield GM Liu X Xu C et al.Primary biliary cirrhosis associated with HLA. IL12A. and IL12RB2 variants.N Engl J Med. 2009; 360: 2544-2555Crossref PubMed Scopus (512) Google Scholar, 3Liu X Invernizzi P Lu Y et al.Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.Nat Genet. 2010; 42: 658-660Crossref PubMed Scopus (335) Google Scholar, 4Mells GF Floyd JA Morley KI et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.Nat Genet. 2011; 43: 329-332Crossref PubMed Scopus (389) Google Scholar). A major effect of IL-12 signaling is TH1 polarization of the acquired immune response. In PBC, variation in IL-12 signaling may lead to inappropriate and sustained TH1 responses. Alternatively, variation in IL-12 signaling may lead to inefficient TH1 responses to appropriate stimuli. It is plausible that either mechanism could lead to disease: PBC in the native liver as well as rPBC in the liver allograft. The association between rPBC and choice of CNI has been previously described (5Silveira MG Talwalkar JA Lindor KD et al.Recurrent primary biliary cirrhosis after liver transplantation.Am J Transplant. 2010; 10: 720-726Abstract Full Text Full Text PDF PubMed Scopus (64) Google Scholar). Tacrolimus and Cyclosporin use different mechanisms to block expression of interleukin-2 (IL-2), which influences IL-12-dependent IFN-gamma production and has a critical role in the regulation of growth, differentiation and survival of activated T cells. It is unclear how IL-2 inhibition or the interaction of IL-2 and IL-12 signaling pathways might influence disease recurrence. This study has notable weaknesses. In particular, the study was underpowered to identify the modest effects of common genetic variants, compounded by a poorly defined phenotype. Nevertheless, finding association at the IL12A locus suggests that mechanisms causing PBC in the allograft might be similar to those causing PBC in the native liver. Hence, LT may provide a unique setting to examine the pathophysiology of PBC. Using protocol biopsies to pinpoint the onset of disease, it might be possible to elucidate the innate and adaptive immune processes active at the earliest stage of disease. We therefore believe that the substantial effort required for better-powered genetic and translational studies of rPBC are justified. We gratefully acknowledge the UK PBC Consortium and the Wellcome Trust Case Control Consortium for granting access to the UK PBC database of the WTCCC3 iCHIP Study of PBC. Marco Carbone was supported by a Short-term Sheila Sherlock Fellowship from EASL. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.
DOI: 10.1111/ajt.12132
Language: English
Topic: Liver Diseases and Immunity
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,300
OpenAlex ID: W2040959818
